Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2024 08:00 ET | Source: Helio Genomics

Helio Genomics Presented CLiMB Trial Data Evaluating HelioLiver for Detecting Early-Stage HCC and Methylation Model Score for Assessing Prognosis at AASLD and Virtual KOL Event, Featuring Chief Medical Advisor Dr. Richard Van Etten, MD, PhD

IRVINE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...
November 19, 2024 12:23 ET | Source: Helio Genomics

Helio Genomics to Host Virtual KOL Event to Discuss Recent CLiMB Trial Data and Methylation Model Score in Patients with Hepatocellular Carcinoma (HCC) on November 25, 2024

IRVINE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...
November 12, 2024 08:00 ET | Source: Helio Genomics

Helio Genomics’ Chief Medical Advisor to Present Superior Performance of the Company’s Multi-Analyte Blood Test, HelioLiver, for Early Cancer Detection at the 2024 American Association for the Study of Liver Diseases Annual Meeting

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...
October 25, 2024 14:10 ET | Source: Helio Genomics

Helio Genomics and Halub Medical Co. Announce Strategic Partnership to Commercialize HelioLiver Dx in The Gulf Cooperation Council and Middle East

IRVINE, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven biotechnology company specializing in diagnostics technology and test development for cancer...
October 14, 2024 08:00 ET | Source: Helio Genomics

Helio Genomics’ Methylation Model Score for Assessing Prognosis and Treatment Response in Patients with Hepatocellular Carcinoma Presented as Top Abstract at the 2024 San Antonio Liver Cancer Symposium

IRVINE, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...
October 03, 2024 16:05 ET | Source: Helio Genomics

Helio Genomics Methylation Model Score for Early Cancer Detection Awarded as a Top Abstract for the 2024 San Antonio Liver Cancer Symposium

IRVINE, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...
August 05, 2024 08:00 ET | Source: Helio Genomics

Helio Genomics Appoints Eric Ariazi, Ph.D. as Chief Development Officer

IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...
July 24, 2024 09:00 ET | Source: Helio Genomics

Helio Genomics to Participate in the 2024 UBS Genomic Medicine Summit

IRVINE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...
July 02, 2024 08:00 ET | Source: Helio Genomics

Helio Genomics Announces Separation from Laboratory for Advanced Medicine, a Cayman Holding Company

IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...
June 10, 2024 08:00 ET | Source: Helio Genomics

Helio Genomics’ HelioLiver Dx Test Meets Coprimary and Secondary Study Endpoints in the CLiMB Trial, Presented at the EASL Congress 2024

IRVINE, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer...